Access IBEC scientific production portal (IBEC CRIS), for more detailed information and advanced search features.
Find here the list of all IBEC's publications by year.
by Keyword: Histone deacetylase
Fallica, Antonino N, Barbaraci, Carla, Ruiz-cantero, M Carmen, Scarlatti, Arianna, Coco, Alessandro, Giordano, Giorgia, La Mantia, Alfonsina, Prezzavento, Orazio, Di Stefano, Antonio, Cacciatore, Ivana, Siano, Giacomo, Cattaneo, Antonino, Pasquinucci, Lorella, Cobos, Enrique J, Di Primio, Cristina, Amata, Emanuele, Marrazzo, Agostino, (2026). Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ1R Agonists/HDAC Inhibitor Dual-Acting Compounds ChemMedChem 21, e202500922 
Neurodegenerative diseases, like Alzheimer's disease (AD), are characterized by the accumulation of tau aggregates, leading to neuronal dysfunction and cognitive decline. This study explores the development of dual-acting compounds combining sigma-1 receptor (sigma R-1) agonists and histone deacetylase inhibitors (HDACi) to target these pathological mechanisms. Compounds 2d and 3a demonstrated high affinity for sigma R-1 and significantly reduced tau aggregation and phosphorylation in vitro, notably at the AT8 epitope. These dual-acting compounds destabilized tau aggregates, increased tau solubility, and showed favorable pharmacokinetic properties, with compound 2d exhibiting enhanced chemical stability and longer half-life than 3a. In vivo, both compounds confirmed a sigma R-1 agonist profile by reversing the effect of the sigma R-1 antagonist BD-1063. This dual-action approach, acting on both HDAC and sigma R-1 pathways, holds significant potential for treating tauopathies. While further optimization and clinical evaluation are needed, these findings provide a strong foundation for the continued development of multimodal therapies for neurodegenerative diseases treatment.
JTD Keywords: Alzheimers, Amyloid-beta, Anavex2-73, Dual-acting compounds, Hdac inhibitors, Histone deacetylase, Ligands, Neurodegenerative diseases, Neuroprotection, Pathogenesis, Phenylbutyrate, Phenylbutyric acid, Phosphorylation, Sigma 1r agonists, Sigma receptors (sigma rs), Sigma(1) receptors, Tau protein, Valproic acid
Alcon, C, Martín, F, Prada, E, Mora, J, Soriano, A, Guillén, G, Gallego, S, Roma, J, Samitier, J, Villanueva, A, Montero, J, (2022). MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment Cell Death Discovery 8, 172
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due to tumor adaptations. We used dynamic BH3 profiling to identify targeted agents effectiveness and anti-apoptotic adaptations upon targeted treatment in rhabdomyosarcoma. We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. We observed that the MEK1/2 inhibitor trametinib rapidly depleted the pro-apoptotic protein NOXA, thus increasing MCL-1 availability. Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. In conclusion, our findings indicate that the combination of a BH3 mimetic targeting MCL-1 with trametinib improves efficiency on rhabdomyosarcoma by blocking tumor adaptation to treatment.
JTD Keywords: apoptosis, bcl-2, combination, expression, pathway, resistance, survival, therapy, tumors, Histone deacetylase inhibitor
